PD-0184: Protective effect of leuprorelin on radiation-induced intestinal toxicity  by Mangoni, M. et al.
S72  2nd ESTRO Forum 2013	
  
Conclusions: The subtraction method described here validates the x-
ray markers as an accurate surrogate for the HDR brachytherapy 
source position. These markers were then appropriate references for 
validation of the algorithm used to determine source position in a two 
dimensional plane parallel to the imaging panel, as derived using an 
EPID based delivery validation system described elsewhere at this 
meeting. EPID measurements of source position were confirmed to be 
accurate within ± 1 mm at source-detector distances up to 200 mm. 
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Purpose/Objective: Prostate cancer patients treated with 
neoadjuvant androgen ablation experience less radiation-induced 
intestinal toxicity. This can be due to the size reduction of bulky 
prostatic tumours and optimization of the target volume. The aim of 
this study was to evaluate if leuprorelin exerts itself a protective 
effect on irradiated bowel. 
Materials and Methods: C57BL/6J mice underwent 12Gy total body 
irradiation (TBI), with or without a monthly i.p. injection of 
leuprorelin (enantone®, 0.054 mg/Kg), started three months before 
TBI. Mice were sacrificed 24 or 72h after TBI and small bowel 
(jejunum, ileum) segments were collected for histological and 
molecular analysis. 
Microcolony survival assay was also performed, to evaluate radiation-
induced damage on crypts and the potential protective effect of 
leuprorelin. Radioprotection was correlated with crypt regeneration; 
crypts containing at least 10 viable cells were considered regenerating 
crypts.  
Results: At hematoxylin eosin staining, untreated controls showed 
normal jejunal wall features,with long villi and well developed tubular 
glands. Irradiation caused a time-dependent reduction of the tubular 
glands and occurrence of a marked inflammatory infiltrate. euprorelin 
pre-treatment appeared to blunt the radiation-induced changes: the 
columnar epithelium mostly showed normal features, with continuous 
striated border and intercalated goblet cells; the inflammatory 
infiltrate in the mucosal/submucosal stroma was markedly reduced in 
comparison with the irradiated mice. 
Real-Time RT-PCR analysis showed that leuprorelin significantly 
decreased radiation-induced collagen type I and type III, TGFbeta, 
Mmp2, Mmp13 and p53 gene expression in the jejunum of treated 
mice. 
Leuprorelin pre-treatment was also able to inhibit TGFbeta and p-
NFkB protein expression induced by irradiation in the jejunum, as 
revealed by western blot analysis. 
Pre-irradiation administration of leuprorelin significantly increased 
the number of regenerating crypts in the jejunum, as compared to 
mice undergone irradiation alone.  
Conclusions: Pretreatment with leuprorelin exerts a protective effect 
against radiation-induced intestinal injury in mice. These findings 
confirm clinical observations in irradiated prostate cancer patients 
and suggest that prostate size reduction is not the only mechanism at 
the basis of better intestinal tolerance after neoadjuvant androgen 
ablation. More investigations are needed to establish a possible way of 
action for the reported effect of leuprorelin on irradiated intestinal 
mucosa  
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Purpose/Objective: The introduction of flattening filter free (FFF) 
photon beams to deliver higher instantaneous dose rates and 
shortened overall treatment times, re-introduced controversy about 
the biological consequences of these high dose rates. We hypothesize 
that high dose rate irradiation will decrease cell survival in normal 
and cancer cell lines and even more in cancer cells deficient for 
homologous recombination. Additionally, we hypothesize that removal 
of the flattening filter will result in an enhanced relative biological 
effectiveness (RBE), independently of the dose rate. 
Materials and Methods: Human breast adenocarcinoma (MCF7), 
colorectal adenocarcinoma (HCT116 and DLD1), glioblastoma (U373 
and U87) and non small cell lung adenocarcinoma (A549) cells were 
irradiated in the range 0 - 10 Gy. Additionally, DNA repair deficient 
HCT116 (DNA-PKcs-/-, NHEJ deficient) or DLD1 (BRCA2-/-, HR 
deficient) and normal breast (MCF10A) and lung bronchial (NL20) 
epithelial cell lines were exposed to similar dose schedules. To 
investigate the effect of high dose rate irradiation, clonogenic survival 
was assessed after exposing cells to 4 or 24 Gy/min FFF using a Varian 
TrueBeam accelerator (10 MV). Additionally, to investigate the effect 
of flattening filter removal on cell survival, cells were exposed to 4 
Gy/min with or without flattening filter. RBE estimations were 
performed comparing the different photon spectra of FF and FFF 
beams. 
Results: Cell survival in tumor or normal tissue cell lines was not 
influenced by high dose rate irradiation. The survival curves for A549 
non small cell lung cancer cells are shown as an example. Although 
DNA repair deficient cell lines showed an increased radiosensitivity, 
high dose rate irradiation did not influence survival. Furthermore, RBE 
was not significantly different from unity in any of the cell lines 
between FFF and conventional flattened beams. 
 
 
Conclusions: High dose rate irradiation did not affect long term cell 
survival and DNA repair for human cancer and normal cell lines of 
different origin. These results suggest that high dose rate does not 
